I en undersøgelse med patienter med fremskreden nyresygdom var effekten af irbesartan på nyrer og kardiovaskulære hændelser ikke den sammei alle sub- grupper.
Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease.